- Report
- May 2025
- 187 Pages
Global
From €3189EUR$3,545USD£2,729GBP
€3544EUR$3,939USD£3,032GBP
- Report
- January 2025
- 176 Pages
Global
From €7152EUR$7,950USD£6,120GBP
- Report
- January 2024
- 114 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- February 2024
- 81 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- March 2025
- 96 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- March 2024
- 73 Pages
Global
From €3500EUR$4,168USD£3,100GBP
- Report
- June 2025
- 50 Pages
Global
From €2384EUR$2,650USD£2,040GBP
- Report
- June 2025
- 50 Pages
Global
From €2384EUR$2,650USD£2,040GBP
- Report
- June 2025
- 50 Pages
Global
From €2384EUR$2,650USD£2,040GBP
Inosine is a nucleoside found in the human body and is used in the treatment of immune disorders. It is used to treat a variety of conditions, including autoimmune diseases, chronic inflammation, and allergies. Inosine is believed to have immunomodulatory properties, which means it can help regulate the immune system and reduce inflammation. It is also thought to have anti-viral and anti-bacterial properties, which can help reduce the severity of infections. Inosine is available in both oral and injectable forms, and is often used in combination with other drugs to treat immune disorders.
Companies in the Inosine market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more